Literature DB >> 21282455

Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole.

A E Paniz Mondolfi1, C Stavropoulos, T Gelanew, E Loucas, A M Perez Alvarez, G Benaim, B Polsky, G Schoenian, E M Sordillo.   

Abstract

Old World cutaneous leishmaniasis is a widespread and potentially disfiguring protozoal infection that is endemic in the Mediterranean basin, Africa, and parts of Asia. Human infection is caused by several species of Leishmania parasites, such as Leishmania infantum. Available systemic and topical treatments vary in efficacy and are often unjustified due to their toxicity. We report on a case that was treated with posaconazole, a drug typically considered an antifungal agent but which also targets specific metabolic pathways of the parasite.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21282455      PMCID： PMC3067187          DOI： 10.1128/AAC.01498-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites.

Authors:  J A Urbina
Journal:  Parasitology       Date:  1997       Impact factor: 3.234

2.  Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.

Authors:  Chiung-Kuang Chen; Siegfried S F Leung; Christophe Guilbert; Matthew P Jacobson; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2010-04-06

3.  Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases.

Authors:  H M Al-Abdely; J R Graybill; D Loebenberg; P C Melby
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies.

Authors:  A D Bryceson; J D Chulay; M Ho; M Mugambii; J B Were; R Muigai; C Chunge; G Gachihi; J Meme; G Anabwani
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

5.  Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes.

Authors:  D H Beach; L J Goad; G G Holz
Journal:  Mol Biochem Parasitol       Date:  1988-11       Impact factor: 1.759

6.  In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.

Authors:  F Faraut-Gambarelli; R Piarroux; M Deniau; B Giusiano; P Marty; G Michel; B Faugère; H Dumon
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes.

Authors:  H Rangel; F Dagger; A Hernandez; A Liendo; J A Urbina
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit.

Authors:  E Caumes; J Carrière; G Guermonprez; F Bricaire; M Danis; M Gentilini
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

9.  Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.

Authors:  M Gramiccia; L Gradoni; S Orsini
Journal:  Ann Trop Med Parasitol       Date:  1992-12

10.  Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.

Authors:  J A Urbina; G Payares; L M Contreras; A Liendo; C Sanoja; J Molina; M Piras; R Piras; N Perez; P Wincker; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
View more
  17 in total

Review 1.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.

Authors:  Gustavo Benaim; Vanessa Hernandez-Rodriguez; Sheira Mujica-Gonzalez; Lourdes Plaza-Rojas; May Li Silva; Nereida Parra-Gimenez; Yael Garcia-Marchan; Alberto Paniz-Mondolfi; Graciela Uzcanga
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

3.  Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Authors:  April C Joice; Sihyung Yang; Abdelbasset A Farahat; Heidi Meeds; Mei Feng; Junan Li; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

4.  VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.

Authors:  Galina I Lepesheva; Tatiana Y Hargrove; Girish Rachakonda; Zdzislaw Wawrzak; Sébastien Pomel; Sandrine Cojean; Pius N Nde; W David Nes; Charles W Locuson; M Wade Calcutt; Michael R Waterman; J Scott Daniels; Philippe M Loiseau; Fernando Villalta
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

5.  Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.

Authors:  Laura Friggeri; Tatiana Y Hargrove; Girish Rachakonda; Anna L Blobaum; Paxtyn Fisher; Gabriel Melo de Oliveira; Cristiane França da Silva; Maria de Nazaré C Soeiro; W David Nes; Craig W Lindsley; Fernando Villalta; F Peter Guengerich; Galina I Lepesheva
Journal:  J Med Chem       Date:  2018-11-30       Impact factor: 7.446

6.  Voriconazole suppresses the growth of Leishmania species in vitro.

Authors:  Manjusha M Kulkarni; Niveditha Reddy; Tulasi Gude; Bradford S McGwire
Journal:  Parasitol Res       Date:  2013-02-08       Impact factor: 2.289

7.  CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds.

Authors:  Tatiana Y Hargrove; Kwangho Kim; Maria de Nazaré Correia Soeiro; Cristiane França da Silva; Denise da Gama Jaen Batista; Marcos Meuser Batista; Eugenia M Yazlovitskaya; Michael R Waterman; Gary A Sulikowski; Galina I Lepesheva
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-06-30       Impact factor: 4.077

8.  Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis.

Authors:  S T de Macedo-Silva; G Visbal; J A Urbina; W de Souza; J C F Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

Review 9.  CYP51 as drug targets for fungi and protozoan parasites: past, present and future.

Authors:  Galina I Lepesheva; Laura Friggeri; Michael R Waterman
Journal:  Parasitology       Date:  2018-04-12       Impact factor: 3.234

10.  Synthesis and Antileishmanial Evaluation of Arylimidamide-Azole Hybrids Containing a Phenoxyalkyl Linker.

Authors:  Ahmed Abdelhameed; Mei Feng; April C Joice; Emilia M Zywot; Yiru Jin; Chris La Rosa; Xiaoping Liao; Heidi L Meeds; Yena Kim; Junan Li; Craig A McElroy; Michael Zhuo Wang; Karl A Werbovetz
Journal:  ACS Infect Dis       Date:  2021-02-04       Impact factor: 5.578
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.